The influence of the degree of activity of rheumatoid arthritis on the parameters of stable metabolites of nitric oxide
DOI:
https://doi.org/10.62480/tjms.2023.vol25.pp75-78Keywords:
Rheumatoid arthritis, nitric oxide metabolites, red blood cellsAbstract
Rheumatoid arthritis (RA) is an immunoinflammatory disease characterized by progressive destruction of joints and damage to internal organs, which is based on disturbances in the humoral and cellular immune system [1,2]. In the absence of effective therapy, life expectancy in patients with RA is lower by 3 years in women and 7 years in men, primarily due to the high risk of developing comorbid diseases [5].
References
Nasonov E.L., Karateev D.E., Balabanova R.M. Rheumatoid arthritis. In the book: Rheumatology. National leadership. Ed. E.L. Nasonova, V.A. Nasonova. Moscow: GEOTAR-Media; 2008. pp. 290-331
Smolen JS, Aletaha D, McNenes IB. Rheumatoid arthritis. Lancet 2016; 22; 388(10055): 2023-2038. doi: 10.1016/S0140-6736(16)30173-8
McClennes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017; 389(10086): 2328-2337. doi: 10.1016/S0140-6736(17)31472-1
McGonagle D, Watad A, Savic S. Mechanistic immunological based classification of rheumatoid arthritis. Autoimmun Rev. 2018; 17(11): 1115-1123. doi: 10.1016/j.autrev.2018.06.001
Firestein GS. Kelley and Firestein's Textbook of Rheumatology. 10th ed. Philadelphia, Pennsylvania: Elsevier; Etiology and pathogenesis of rheumatoid arthritis. 2016 1115-66
Zenkov N.K., Menshikov E.B., Reutov V.P. NO synthases in normal conditions and in pathologies of various origins // Vesti. RAMS. -2000. -No. 4. – P.30-34.
Kukes V.G. Features of pharmacokinetics, lipid-lowering and clinical effectiveness of fluvostatin EL // Clinical Pharmacol. and therapy. -2004. –T., No. 3. –P.54-57.
Markov Kh.M. Molecular mechanisms of vascular endothelial dysfunction //Cardiology. -2005. No. 12. –P.62-7 2.
Azimov R.K., Komarin A.S. Pathophysiology of nitrogen monoxide metabolism. Recommendation method. – Tashkent, 2005. -29 p.
Valesini G., Barone F., Bompane D., Catuogno M. A. Sili Scavalli // Reumatismo. – 2004. No. 56. - P.9-20
Kahlenberg J.M., Fox D.A. Advances in the Medical Treatment of Rheumatoid Arthritis // Hand Clin. – 2011. 27(1). – p.11–20.
Imanaeva A.Ya., Zalyalutdinova L.N. Pathogenetic rationale for the use of antioxidants in the treatment of rheumatoid arthritis // Modern problems of science and education. – 2013. – No. 2.;
URL: https://science-education.ru/ru/article/view?id=9036
Topchieva L.V., Balan O.V., Malysheva I.E., Barysheva O.Yu., Marusenko I.M., Vaskova O.A. The content of nitric oxide metabolites and the level of nos2 gene transcripts in rheumatoid arthritis. Molecular Medicine, 2018; (4): -ttps://doi.org/10.29296/24999490-2018-04-03
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
User Rights
Under the Creative Commons Attribution-NonCommercial 4.0 International (CC-BY-NC), the author (s) and users are free to share (copy, distribute and transmit the contribution).
Rights of Authors
Authors retain the following rights:
1. Copyright and other proprietary rights relating to the article, such as patent rights,
2. the right to use the substance of the article in future works, including lectures and books,
3. the right to reproduce the article for own purposes, provided the copies are not offered for sale,
4. the right to self-archive the article.
